EA200200416A1 - Кристаллы ингибитора натрий-водородного обмена 1 типа - Google Patents

Кристаллы ингибитора натрий-водородного обмена 1 типа

Info

Publication number
EA200200416A1
EA200200416A1 EA200200416A EA200200416A EA200200416A1 EA 200200416 A1 EA200200416 A1 EA 200200416A1 EA 200200416 A EA200200416 A EA 200200416A EA 200200416 A EA200200416 A EA 200200416A EA 200200416 A1 EA200200416 A1 EA 200200416A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystals
type
sodium hydrogen
inhibitor
hydrogen exchange
Prior art date
Application number
EA200200416A
Other languages
English (en)
Other versions
EA004937B1 (ru
Inventor
Лайл Робинсон Бростром
Терренс Джозеф Коннолли
Зенг Джэйн Ли
Сьюзан Ли Оррилл
Бхарат Кириткумар Шах
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200200416A1 publication Critical patent/EA200200416A1/ru
Publication of EA004937B1 publication Critical patent/EA004937B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Кристаллическое соединение, представляющее собой ингибитор обмена Na/Hтипа 1 (NHE-1), способы применения такого кристаллического соединения - ингибитора NHE-1 и фармацевтические композиции, содержащие такое кристаллическое соединение. Кристаллы ингибитора NHE-1 применяются для уменьшения повреждения ткани в результате ишемии ткани.Отчет о международном поиске был опубликован 2001.09.13.
EA200200416A 1999-10-29 2000-10-09 Кристаллы ингибитора натрий-водородного обмена 1 типа EA004937B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (2)

Publication Number Publication Date
EA200200416A1 true EA200200416A1 (ru) 2002-10-31
EA004937B1 EA004937B1 (ru) 2004-10-28

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200416A EA004937B1 (ru) 1999-10-29 2000-10-09 Кристаллы ингибитора натрий-водородного обмена 1 типа

Country Status (44)

Country Link
EP (1) EP1224179B1 (ru)
JP (1) JP2003512455A (ru)
KR (1) KR100464526B1 (ru)
CN (2) CN1636991A (ru)
AP (1) AP2002002493A0 (ru)
AR (1) AR029402A1 (ru)
AT (1) ATE271047T1 (ru)
AU (1) AU778573B2 (ru)
BG (1) BG106729A (ru)
BR (1) BR0015275A (ru)
CA (1) CA2389020A1 (ru)
CO (1) CO5271714A1 (ru)
CZ (1) CZ20021332A3 (ru)
DE (1) DE60012208T2 (ru)
DK (1) DK1224179T3 (ru)
DZ (1) DZ3463A1 (ru)
EA (1) EA004937B1 (ru)
EE (1) EE200200227A (ru)
ES (1) ES2222923T3 (ru)
GE (1) GEP20043222B (ru)
GT (1) GT200000180A (ru)
HK (1) HK1048472B (ru)
HR (1) HRP20020366B1 (ru)
HU (1) HUP0204009A3 (ru)
IL (1) IL148581A0 (ru)
IS (1) IS6302A (ru)
MA (1) MA26840A1 (ru)
MX (1) MXPA02004358A (ru)
NO (1) NO20021821D0 (ru)
NZ (1) NZ517738A (ru)
OA (1) OA12080A (ru)
PA (1) PA8505501A1 (ru)
PE (1) PE20010764A1 (ru)
PL (1) PL354869A1 (ru)
PT (1) PT1224179E (ru)
SI (1) SI1224179T1 (ru)
SK (1) SK5312002A3 (ru)
SV (1) SV2002000209A (ru)
TN (1) TNSN00210A1 (ru)
TR (1) TR200201167T2 (ru)
UA (1) UA72002C2 (ru)
WO (1) WO2001030759A2 (ru)
YU (1) YU31502A (ru)
ZA (1) ZA200203295B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
BR0116841A (pt) * 2001-01-31 2004-02-25 Pfizer Producs Inc Etanolatos de inibidor de permutador sódio-hidrogênio do tipo-1
EP1472242A1 (en) * 2002-01-30 2004-11-03 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU46200A (sh) * 1998-02-27 2003-02-28 Pfizer Products Inc. N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije

Also Published As

Publication number Publication date
EA004937B1 (ru) 2004-10-28
EP1224179A2 (en) 2002-07-24
MA26840A1 (fr) 2004-12-20
HRP20020366A2 (en) 2004-02-29
EP1224179B1 (en) 2004-07-14
UA72002C2 (en) 2005-01-17
TNSN00210A1 (fr) 2005-11-10
DE60012208T2 (de) 2005-07-21
NZ517738A (en) 2005-06-24
OA12080A (en) 2003-08-25
IS6302A (is) 2002-03-15
EE200200227A (et) 2003-06-16
CA2389020A1 (en) 2001-05-03
CO5271714A1 (es) 2003-04-30
HK1048472A1 (en) 2003-04-04
HUP0204009A2 (hu) 2003-03-28
CN1205205C (zh) 2005-06-08
GT200000180A (es) 2002-04-11
CN1384829A (zh) 2002-12-11
KR100464526B1 (ko) 2005-01-03
PT1224179E (pt) 2004-10-29
YU31502A (sh) 2004-12-31
CN1636991A (zh) 2005-07-13
SV2002000209A (es) 2002-07-16
ES2222923T3 (es) 2005-02-16
PL354869A1 (en) 2004-03-08
DE60012208D1 (de) 2004-08-19
MXPA02004358A (es) 2002-11-07
ZA200203295B (en) 2003-06-25
NO20021821L (no) 2002-04-18
PA8505501A1 (es) 2003-09-05
HUP0204009A3 (en) 2004-07-28
BG106729A (bg) 2002-12-29
HRP20020366B1 (en) 2005-04-30
DK1224179T3 (da) 2004-10-25
PE20010764A1 (es) 2001-07-23
CZ20021332A3 (cs) 2002-10-16
AU7441500A (en) 2001-05-08
DZ3463A1 (fr) 2001-05-03
AU778573B2 (en) 2004-12-09
GEP20043222B (en) 2004-04-26
TR200201167T2 (tr) 2002-08-21
AP2002002493A0 (en) 2002-06-30
WO2001030759A2 (en) 2001-05-03
NO20021821D0 (no) 2002-04-18
SI1224179T1 (en) 2004-10-31
AR029402A1 (es) 2003-06-25
BR0015275A (pt) 2002-07-16
JP2003512455A (ja) 2003-04-02
WO2001030759A3 (en) 2001-09-13
HK1048472B (zh) 2005-09-16
KR20020040918A (ko) 2002-05-30
SK5312002A3 (en) 2003-01-09
ATE271047T1 (de) 2004-07-15
IL148581A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
DK1485359T3 (da) Natriumkanalblokkere
DK1140918T3 (da) Thrombininhibitorer
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
DK1001930T3 (da) N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
EA200000826A1 (ru) Галоидированные производные амидиноаминокислот, применимые в качестве ингибиторов no-синтазы
EA200200819A1 (ru) Кристаллическая форма ii линезолида
EA200400129A1 (ru) Способ получения периндоприла, его аналогов и солей с использованием 2,5-диоксооксазолидиновых промежуточных соединений
DE3887048D1 (de) Flüssigkristalline, insbesondere ferroelektrische flüssigkristalline Mischungen.
DE59902779D1 (de) Kristallmodifikation der liponsäure
HRP20000585B1 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
EA200200416A1 (ru) Кристаллы ингибитора натрий-водородного обмена 1 типа
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
TR199802297T2 (xx) Eritromisin t�revlerinin 10-metil radikallerinin izomerizasyonu i�in yeni y�ntem.
EA200201023A1 (ru) Ингибитор натрий-водородного обмена типа 1(nhe-1)
NO20022977L (no) Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
DK0745081T3 (da) Indan-2-mercaptoacetylamiddisulfidderivater, der er anvendelige som enkephalinase-inhibitorer
FI962322A0 (fi) (S,S,S)-N-(1-(2-karboksi-3-(N2-mesyylilysyyliamino)propyyli)1-syklopentyylikarbonyylityrosiinin kiteinen polymorfinen muoto
BG104554A (en) Thermodynamically stable form of (r)-3-[(-4-fluorophenyl) sulphonyl]amino 1,2,3,4-tetrahydro-9h-carbazole-9-propanoic acid (ramatroban)
YU43499A (sh) Kristalna hidratovana natrijumova so (e)-4,6-dihloro-3- (2-okso-1-fenilpirolidin-3-iliden metil)-1h-indol-2- karboksilne kiseline
FI961423A (fi) Antrasykliinidisakkaridit, menetelmä niiden valmistamiseksi sekä niitä sisältävät farmaseuttiset koostumukset
FI960588A (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
AU553914B2 (en) Derivatives of n - (4-phenylcyclohexyl) glycines
ES2099621T3 (es) Procedimiento para producir un derivado de imidazol.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU